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Abstract
Background: Microglia are the resident macrophage population of the central nervous system (CNS) and play
essential roles, particularly in inflammation-mediated pathological conditions such as ischemic stroke. Increasing
evidence shows that the population of vascular cells located around the blood vessels, rather than circulating cells,
harbor stem cells and that these resident vascular stem cells (VSCs) are the likely source of some microglia.
However, the precise traits and origins of these cells under pathological CNS conditions remain unclear.
Methods: In this study, we used a mouse model of cerebral infarction to investigate whether reactive pericytes
(PCs) acquire microglia-producing VSC activity following ischemia.
Results: We demonstrated the localization of ionized calcium-binding adaptor molecule 1 (Iba1)-expressing
microglia to perivascular regions within ischemic areas. These cells expressed platelet-derived growth factor
receptor-β (PDGFRβ), a hallmark of vascular PCs. PDGFRβ+ PCs isolated from ischemic, but not non-ischemic, areas
expressed stem/undifferentiated cell markers and subsequently differentiated into various cell types, including
microglia-like cells with phagocytic capacity.
Conclusions: The study results suggest that vascular PCs acquire multipotent VSC activity under pathological
conditions and may thus be a novel source of microglia.
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Background
Microglia, a glial cell subtype, comprise the resident
macrophage population located within the central ner-
vous system (CNS). The precise origin of microglia has
long remained the subject of debate [1, 2]. Previous
studies have demonstrated that microglia originate from
progenitor cells in the embryonic yolk sac during early
development and that embryonically derived microglia
self-maintain until adulthood under normal conditions
[3, 4]. Nevertheless, it remains unclear whether these
cells can continuously produce microglia in the adult
CNS, even under pathological conditions. It has been
proposed that some microglia originate from bone-
marrow-derived hematopoietic cells or circulating
monocytes [5–7]. However, it remains controversial
whether new microglia do indeed originate from bone
marrow cells [8], suggesting the potential for other
sources of microglia within the adult CNS.
Mounting evidence suggests that progenitor cells local-
ized to the adventitia (adventitial progenitor cells (APCs))
around the blood vessels may serve as multipotent resi-
dent vascular stem cells (VSCs) [9] that contribute to vas-
culogenesis [10–12]. A recent study by Psaltis and
colleagues demonstrated that macrophage progenitors can
derive from APCs located in the adult murine aorta [13].
In addition to the APCs near larger vessels, vascular peri-
cytes (PCs) located around capillaries are also strong
candidate sources for the VSC population [9, 14]. PCs ex-
hibit the potential for differentiation into multiple differ-
ent cell populations, including neural cells, adipocytes,
* Correspondence: nakagomi@hyo-med.ac.jp
1Institute for Advanced Medical Sciences, Hyogo College of Medicine, 1-1
Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan
Full list of author information is available at the end of the article
© 2016 Sakuma et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sakuma et al. Journal of Neuroinflammation  (2016) 13:57 
DOI 10.1186/s12974-016-0523-9
chondroblasts, and osteoblasts [15, 16]. Although it re-
mains controversial whether PCs can produce microglia
[17–19], we recently demonstrated that PCs acquire mul-
tipotent stem cell activity in response to brain injuries
such as ischemia/hypoxia and that these reactive PCs
can differentiate into various lineages, including the
neural and vasculogenic lineages [20]. In addition, brain
multipotent stem cells exhibit microglia-like cell pheno-
types [21, 22] and microglia have been described as aris-
ing from meningeal cells [2, 23]. We demonstrated that
substantial quantities of multipotent PCs were derived
from the latter cells following ischemic stroke [20, 24–27].
These findings led us to hypothesize that resident micro-
glia might originate from ischemia-induced multipotent
PCs following CNS injury.
In this study, we used a mouse model of cerebral in-
farction to investigate whether reactive PCs develop the
traits of microglia-producing VSCs following ischemia.
Methods
Induction of focal cerebral ischemia
The Animal Care Committee of the Hyogo College of
Medicine approved all experimental procedures (license
number: 12-064). Six-week-old male CB-17/Icr-+/+Jcl
mice (CB-17 mice; Clea Japan Inc., Tokyo, Japan) were
subjected to cerebral ischemia as described previously
[20, 25, 28–30]. Permanent focal cerebral ischemia was
produced by ligation and interruption of the distal portion
of the left middle cerebral artery (MCA) [20, 25, 28–30].
Under halothane inhalation, the left MCA was isolated,
electrocauterized, and disconnected just distal to the point
where it crosses the olfactory tract (the distal M1 portion).
Isolation of PDGFRβ+ pericytes following ischemia
Post-ischemia PCs (iPCs) were extracted from post-stroke
CB-17 mice as described previously [20, 25, 28–30].
Briefly, mice were deeply anesthetized with sodium pento-
barbital (50 mg/kg) on post-stroke day 3. The post-
ischemic areas, which contained leptomeninges harboring
abundant iPCs [25, 26], were carefully removed under a
microscope (Carton, Pathum Thani, Thailand). The re-
moved tissues were mechanically dissociated by passage
through 18-, 23-, and 27-gauge needles to create a single-
cell suspension. The resulting cell suspensions were incu-
bated with adherent cultures in DMEM/F12 medium
(Invitrogen, Carlsbad, CA, USA) containing fibroblast
growth factor-basic (bFGF 20 ng/mL; Peprotech, Rocky
Hill, NJ, USA), epidermal growth factor (EGF 20 ng/mL;
Peprotech), 1 % N2 supplement (Invitrogen), and 2 % fetal
bovine serum (FBS). On incubation day 7, the expanded
PCs were subjected to magnetic cell sorting (MACS) as
described previously [20, 25]. The MACS-sorted platelet-
derived growth factor receptor-β (PDGFRβ+) iPCs were
reincubated with floating cultures in neural-conditioned
medium (NCM; DMEM/F12, EGF, FGF-2, and N2)
[25, 28–30]. After incubation, PDGFRβ+ iPCs that
formed clusters were subjected to immunohistochem-
istry, cell differentiation, electron microscopy, reverse
transcriptase-polymerase chain reaction (RT-PCR),
and phagocytosis analyses.
Immunohistochemistry
Coronal brain sections were prepared and subjected to im-
munohistochemistry as described previously [25, 28–30].
Briefly, mice were anesthetized with sodium pentobarbital
and perfused transcardially with 4 % paraformaldehyde on
days 3, 5, and 7 after stroke. The perfused brains were re-
moved, cryoprotected in 30 % sucrose, and sectioned on a
cryostat. Samples were labeled with antibodies against ion-
ized calcium binding adaptor molecule 1 (Iba1; Abcam,
Cambridge, UK), PDGFRβ (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), CD31 (BD Pharmingen, San Diego,
CA, USA), α-smooth muscle actin (αSMA; Millipore, Te-
mecula, CA, USA), nestin (Millipore), and Sox2 (Millipore).
PDGFRβ+ iPC-derived clusters were fixed in paraformalde-
hyde (4 %) and cut on a cryostat, and the resulting tissue
sections were subjected to immunohistochemistry. Samples
were labeled with antibodies against nestin (Millipore),
PDGFRβ (Santa Cruz Biotechnology), neural/glial antigen 2
(NG2; EMD/Millipore, Billerica, MA, USA), αSMA (Life-
Span Biosciences, Seattle, WA, USA), Iba1 (Abcam), and
CD68 (Abcam). Bound primary antibodies were visualized
using Alexa Fluor 488- or 555-conjugated secondary
antibodies (Molecular Probes, Eugene, OR, USA). Nuclei
were stained with 4′,6-diamidino-2-phenylindole (DAPI;
Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD,
USA). Brain sections were imaged using a confocal laser
microscope (LSM780; Carl Zeiss, Jena, Germany). For
negative control immunohistochemistry, the primary anti-
bodies were omitted and no staining was confirmed. In
this study, we defined the “ischemic core” as the internal
area within the “border of the post-stroke area” and the
“peri-ischemic area” as the external (non-ischemic) re-
gions within 200 μm of the “border of the post-stroke
area.” The numbers of positive cells were analyzed using
Image J software (a total of 15 data points, 5 points/sec-
tion (n = 3)) and subjected to a semi-quantitative analysis
as described [30, 31]. Other methods for immunohisto-
chemistry are available in Additional file 1.
Cell differentiation
To induce neural differentiation, PDGFRβ+ iPC clusters
were incubated on poly-L-lysine-coated glass coverslips
for 7 days in neurobasal medium (Invitrogen, Carlsbad,
CA, USA) supplemented with B-27 (Invitrogen) and all-
trans retinoic acid (0.2 μM; Sigma, St. Louis, MO, USA)
[20]. Differentiated cells were labeled with antibodies
against Iba1 (Abcam), CD11b (BD Pharmingen), major
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histocompatibility complex (MHC) class 1 (Abcam), and
Tuj1 (Stem Cell Technologies, Vancouver, BC, Canada). To
induce osteoblastic or adipogenic differentiation, PDGFRβ+
iPCs were cultured in osteogenic or adipogenic differenti-
ation medium, respectively, according to the manufacturer’s
protocol (SC 010; R&D systems, Minneapolis, MN, USA).
The resulting differentiated cells were labeled with anti-
bodies against osteopontin (Santa Cruz Biotechnology) or
fatty acid binding protein 4 (FABP4) (R&D Systems),
respectively. Alternatively, PDGFRβ+ iPCs incubated in adi-
pogenic differentiation medium were stained with the lipid-
specific dye Oil Red O as described previously [32].
Electron microscopy
Differentiated cell clusters were sequentially fixed in a
1 % glutaraldehyde and 1 % paraformaldehyde solution
of 0.1-M phosphate buffer, pH 7.4, for 1 h. After a brief
rinse in phosphate buffer, the cell clusters were post-fixed
with 2 % OsO4 in phosphate buffer for 2 h, followed by
methanol dehydration and embedding between Aclar
films (Nisshin EM, Tokyo, Japan) with Epon812. Ultrathin
sections were subsequently cut and collected on Formvar-
coated single-slot grids. The sections were stained with ur-
anyl acetate and Reynolds’ solution and examined with a
JEOL 1220EX transmission electron microscope (JEOL
GmbH, Freising, Germany).
OGD treatment
Commercially available adult normal mouse brain PCs
(PC-N; #M1200, Scien Cell Research Laboratories,
Carlsbad, CA, USA) were incubated under oxygen/glu-
cose deprivation (OGD) (PC-OGD). In brief, the cells
(5.0 × 104 cells/well) were placed on 12-well culture
plates (Iwaki, Tokyo, Japan) in pericyte growth medium
(Scien Cell Research Laboratories). One day later, the
medium was removed and replaced with glucose-free
DMEM and FBS (2 %). PC-OGD were then incubated
under hypoxia (1 % O2) for 7 days using a hypoxia-
inducing system (Bionix, SUGIYAMA-GEN, Tokyo,
Japan) as described previously [20].
RT-PCR
Total RNA was extracted from PDGFRβ+ iPCs, PC-N, and
PC-OGD using an RNeasy Micro Kit (Qiagen, Hilden,
Germany). Complementary DNAs (cDNAs) were amplified
according to the manufacturer’s protocols as described pre-
viously [20, 25, 28]. The following primer sequences were
used in these reactions: PDGFRβ forward, 5′-ACAATTCC
GTGCCGAGTGACAG-3′ and PDGFRβ reverse, 5′-AA
AAGTACCAGTGAAACCTCGCTG-3′ (amplicon size, 1
14 bp); NG2 forward, 5′-ATGCTTCTCAGCCCGGGA
CA-3′ and NG2 reverse, 5′-GGTTGCGGCCATTGAGA
ATG-3′ (amplicon size, 541 bp); αSMA forward, 5′-GG
ACGTACAACTGGTATTGTGC-3′ and αSMA reverse,
5′-TCGGCAGTAGTCACGAAGGA-3′ (amplicon size, 17
9 bp); nestin forward, 5′-CACTAGAAAGCAGGAACCA
G-3′ and nestin reverse, 5′-AGATGGTTCACAATCCT
CTG-3′ (amplicon size, 307 bp); c-myc forward, 5′-AT
GCCCCTCAACGTGAACTTC-3′ and c-myc reverse, 5′-
CGCAACATAGGATGGAGAGCA-3′ (amplicon size, 22
8 bp); Klf4 forward, 5′-GTGCCCCGACTAACCGTTG-3′
and Klf4 reverse, 5′-GTCGTTGAACTCCTCGGTCT-3′
(amplicon size, 185 bp); Sox2 forward, 5′-TTGGGAG
GGGTGCAAAAAGA-3′ and Sox2 reverse, 5′-CCTG
CGAAGCGCCTAACGTA-3′ (amplicon size, 312 bp); Iba1
forward, 5′-GGATTTGCAGGGAGGAAAAG-3′ and Iba1
reverse, 5′-TGGGATCATCGAGGAATTG-3′ (amplicon
size, 92 bp); CD11b forward, 5′-GGGAGGACAAAAACT
GCCTCA-3′ and CD11b reverse, 5′-ACAACTAGGATCT
TCGCAGCAT-3′ (amplicon size, 98 bp); and β-actin
forward, 5′-GCTCGTCGTCGACAAGGGCTC-3′ and β-
actin reverse, 5′-CAAACATGATCTGGGTCATCTTCTC-
3′ (amplicon size, 353 bp).
Phagocytosis assay
To determine whether post-ischemia reactive brain
PCs could potentially give rise to functional microglia
capable of phagocytosis, PDGFRβ+ iPCs were induced
to differentiate and then subjected to treatment with
a Latex Beads-Rabbit IgG-FITC solution, a compo-
nent of a phagocytosis assay kit, according to the
manufacturer’s protocols (Cayman Chemical, Ann
Arbor, MI, USA).
Results
Localization and characterization of microglia following
ischemic stroke
We first examined the localization of Iba1-expressing
microglia following ischemia. In sham-operated mice,
Iba1+ microglia were observed in the MCA areas of
the CNS. These resting microglia displayed a ramified
morphology (Additional file 2: Figure S1A–C). On
post-stroke day 3, Iba1+ microglia accumulated pre-
dominantly in the peri-ischemic areas (Additional file
2: Figure S1D–F). Although some cells still showed a
ramified morphology, this population had decreased
by post-ischemic days 5 (Additional file 2: Figure
S1G–I) and 7 (Additional file 2: Figure S1J–L). In
contrast, ameboid-like activated microglia frequently
appeared in the peri-ischemic areas by post-stroke
day 5 (Additional file 2: Figure S1G–I) and further in-
creased at post-ischemic day 7 (Additional file 2:
Figure S1J–L). Iba1+ cell numbers within the ischemic
core and peri-ischemic areas were determined follow-
ing ischemia (Additional file 2: Figure S1M), with the
populations of ramified- and ameboid-like Iba1+
microglia assessed in both areas (Additional file 2:
Figure S1N).
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Iba1 expression by PDGFRβ+-reactive brain PCs
To determine whether microglia originate, at least in part,
from reactive PCs, we first investigated the localization of
PDGFRβ+ cells following ischemic stroke. Immunohisto-
chemistry showed that PDGFRβ+ cells localized near
CD31+ endothelial cells in and around the ischemic areas
(Fig. 1a, b). Morphologically, PDGFRβ+ cells extend long
cell processes across the surface of endothelial cells, a
characteristic feature also exhibited by PCs [33]. This find-
ing confirmed the expression of PDGFRβ in reactive PCs
following ischemia. We then investigated whether
PDGFRβ+ PCs express Iba1 following ischemic stroke. On
post-stroke day 3, only a small portion of PDGFRβ+ cells
expressed Iba1 (Fig. 1c–f ). However, this number began to
increase on post-stroke day 5 (Fig. 1g–k), suggesting that
PDGFRβ+ iPCs could generate microglia. The number of
Iba1 and PDGFRβ double-positive cells (Fig. 1l) and the
populations of Iba1+ cells relative to PDGFRβ+ cells
(Fig. 1m) were analyzed at post-stroke days 3, 5, and 7
within the ischemic core and peri-ischemic areas.
Fig. 1 Brain PDGFRβ+ PCs express Iba1 following ischemia. At the ischemic site, PDGFRβ+ expression was specifically observed in PCs located
near CD31+ endothelial cells (PDGFRβ (a, b green), CD31 (a, b red), DAPI (a, b blue)). On day 3 post-stroke, only a few PDGFRβ+ iPCs expressed
Iba1 (c–f) (PDGFRβ (d, e red), Iba1 (d, f green), DAPI (d–f blue)) (arrow). However, some Iba1+PDGFRβ+ iPCs were observed in the ischemic areas
on post-stroke day 5 (g–k) (PDGFRβ (h, i, k: red), Iba1 (h, j, k green), DAPI (h–k blue)) (arrows). The numbers of Iba1+ and PDGFRβ+ cells (l) and
populations of Iba1+ cells relative to those of the PDGFRβ+ cells (m) localized to the ischemic core and peri-ischemic areas are shown. Scale bars= 100 μm
(a), 50 μm (b), and 20 μm (d, h, k). Iba1 ionized calcium binding adaptor molecule 1, PDGFRβ platelet-derived growth factor receptor-β
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We further investigated whether PDGFRβ+ cells within
the ischemic areas expressed αSMA. The latter protein
is known to be expressed in perivascular cells and, in
particular, in smooth muscle cells located around large
vessels, rather than in the PCs that surround capillaries
[34]. Consistent with the previous report, αSMA cells
were predominantly observed in smooth muscle cells
and they also expressed PDGFRβ (Fig. 2a–d). This find-
ing suggests that PDGFRβ was expressed not only in
PCs but also in smooth muscle cells. Thus, we examined
whether Ibal+ cells express αSMA following ischemia.
The results indicated that Ibal+ cells rarely expressed
αSMA on post-stroke days 3 (Fig. 2e–h), 5 (Fig. 2i–l),
and 7 (Fig. 2m–p), indicating that microglia originate in
part from perivascular cells and in particular from PCs
rather than smooth muscle cells.
We next investigated whether PDGFRβ+ iPCs express
the microglial markers other than Iba1. Immunohisto-
chemistry at post-stroke day 3 showed that some
PDGFRβ+ cells co-express the microglial marker CD206
[35] (Additional file 3: Figure S2A–D). We then investi-
gated whether PDGFRβ+ cells express CD68, which is
generally known to be expressed by perivascular macro-
phages rather than by microglia [35, 36]. On post-stroke
day 3, CD68+ cells were only rarely observed within the
ischemic core and the peri-ischemic areas (Additional
file 4: Figure S3A–D). CD68+ cells were observed at
these areas on post-stroke day 5 (Additional file 4:
Figure S3E–H) and 7 (Additional file 4: Figure S3I–L)
and some of them expressed Iba1 (Additional file 4:
Figure S3E–L). However, there were fewer CD68+ cells
than Iba1+ cells within these regions. In addition,
Fig. 2 Brain αSMA+ cells rarely express Iba1 following ischemia. Immunohistochemistry showed that αSMA expression was predominantly
observed in the smooth muscle cells located around large vessels that also expressed PDGFRβ (PDGFRβ (a–c red), αSMA (a, b, d green), DAPI
(a–d blue)). However, following ischemia, Ibal+ cells rarely expressed αSMA at post-stroke day 3 (e–h), 5 (i–l), and 7 (m–p) (αSMA (f, g, j, k, n, o red),
Iba1 (f, h, j, l, n, p green), and DAPI (f–h, j–l, n–p blue)). This pattern suggested that microglia originate in part from perivascular cells and in particular
from PCs rather than smooth muscle cells. Scale bars= 50 μm (a) and 20 μm (b, f, j, n) Iba1 ionized calcium binding adaptor molecule 1, PDGFRβ
platelet-derived growth factor receptor-β
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PDGFRβ+ cells at the ischemic core and peri-ischemic
areas rarely express CD68 on post-stroke days 5
(Additional file 4: Figure S3M–P) and 7 (Additional file
4: Figure S3Q–T). These findings were consistent with a
previous report showing that regulator of G-protein sig-
naling 5 (RGS5)+ PCs following ischemic stroke express
Iba1 but not CD68 [36]. Together, these results suggest
that Iba1+ microglia that appear following ischemia are
most likely not derived from perivascular macrophages.
Post-ischemic brain PCs express the stem cell markers
We recently demonstrated that reactive PCs acquire
multipotent stem cell potential following ischemia [20].
Thus, we next examined whether PDGFRβ+ PCs express
the stem cell marker nestin following ischemic stroke.
Although nestin was observed within ischemic areas
(Fig. 3a, b), it was not expressed in non-ischemic areas
on post-stroke day 3 (Fig. 3a, c). In addition, nestin+ cells
within ischemic areas largely (92.5 %) localized near
CD31+ endothelial cells (Fig. 3d–g) and they frequently
(61.1 %) expressed PDGFRβ (Fig. 3h–k). Furthermore,
nestin+ cells within ischemic areas expressed the stem
cell marker Sox2 in the nucleus (Fig. 3l–o), confirming
that nestin+ cells have the traits of stem cells. These re-
sults suggest that PDGFRβ+ PCs within ischemic areas
develop stemness following ischemia.
Brain PCs acquire multipotent VSC activity following
ischemia
To confirm that PDGFRβ+ PCs acquire multipotent VSC
activity in response to ischemia, PDGFRβ+ cells display-
ing PC characteristics were selectively collected from
Fig. 3 Brain PCs express the stem cell markers following ischemia. Brain PCs expressed the neural stem cell marker nestin on post-stroke day 3
(a–c). Although nestin was highly expressed in ischemic areas (a, b), it was rarely observed in non-ischemic areas (a, c) (nestin (b, c red), DAPI
(b, c blue)). Nestin+ cells within the ischemic core were localized near CD31+ endothelial cells (d-g) (nestin (e, f green), CD31 (e, g red), DAPI (e–g blue))
and the majority also expressed PDGFRβ (h-k) (nestin (i, j green), PDGFRβ (i, k red), DAPI (i–k blue)). In addition, nestin+ cells located within ischemic
areas also expressed the stem cell marker Sox2 (l-o) (nestin (m, n green), Sox2 (m, o red), DAPI (m–o blue)). Scale bars = 100 μm (b, c) and 20 μm (e, i,
m) PDGFRβ platelet-derived growth factor receptor-β
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ischemic areas using a MACS-based procedure (Fig. 4a)
as described previously [20]. Immunohistochemistry
revealed that all sorted cells expressed PDGFRβ
(Fig. 4b), confirming the successful collection of
PDGFRβ+ cells. In addition, some PDGFRβ+ cells co-
expressed nestin (Fig. 4c), indicating that PDGFRβ+
Fig. 4 Brain PCs serve as multipotent VSCs following ischemia. Cells were isolated from ischemic areas, and PDGFRβ+ iPCs were selectively
collected using MACS (a). By immunohistochemistry, MACS-sorted cells expressed both PDGFRβ and nestin (PDGFRβ (b, c red), nestin (c green),
DAPI (b, c blue)). After incubation in a floating culture (d), PDGFRβ+ iPCs formed clusters (e). The cells in these clusters expressed nestin (PDGFRβ
(f, g green), nestin (f, h red), DAPI (f–h blue)) and PC cell marker proteins that included NG2 (NG2 (i green), DAPI (i: blue)), and αSMA (αSMA (j green),
DAPI (j blue)). PCR analysis confirmed that the clusters expressed PC markers (PDGFRβ, NG2, and αSMA). In addition, these cells expressed various stem
and undifferentiated cell markers, including nestin, c-myc, Klf4, and Sox2 (k). The PDGFRβ+ iPCs subsequently differentiated into various cell types,
including Tuj1+ neuronal cells (l), osteopontin+ osteoblasts (m), FABP4+ (n), and Oil red+ adipocytes (o). Scale bars= 50 μm (b, e, f, i, j), and 20 μm
(l, m, n, o) FABP4 fatty acid binding protein 4, MACS, magnetic cell sorting, PDGFRβ platelet-derived growth factor receptor-β, VSCs vascular stem cells
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iPCs have stem cell characteristics. To confirm this ob-
servation, MACS-sorted PDGFRβ+ iPCs were incu-
bated in medium under floating culture conditions
(Fig. 4d). Following incubation, these cells formed clus-
ters (Fig. 4e) that were positive for nestin (Fig. 4f–h), as
well as various PC markers such as NG2 (Fig. 4i) and
αSMA (Fig. 4j). PCR analysis also revealed that in addition
to PC marker (e.g., PDGFRβ, NG2, and αSMA) expres-
sion, the clustered cells also expressed various stem and
undifferentiated cell markers, including nestin, c-myc,
Klf4, and Sox2 (Fig. 4k). After differentiation, PDGFRβ+
iPCs revealed their potential for differentiation into
various cell populations, including Tuj1+ neuronal
cells (Fig. 4l), osteopontin+ osteoblasts (Fig. 4m), and
FABP4+ (Fig. 4n) and Oil Red+ adipocytes (Fig. 4o).
However, we could not isolate these cells from non-
ischemic areas as previously described [20, 25, 28].
These results indicate that reactive PDGFRβ+ iPCs
harbor multi-differentiation potential and can function
as VSCs.
Fig. 5 Brain PCs can generate microglia following ischemia. Some of the clustered MACS-sorted PDGFRβ+ iPCs (a) expressed Iba1 (b) (Iba1 (b green),
DAPI (b blue)), but not CD68 (c) (CD68 (c green), DAPI (c blue)). The cell clusters differentiated into Iba1+ and CD11b+ microglia (Iba1 (d, e green),
CD11b (d, f red), DAPI (d–f blue)). The differentiated Iba1+ ameboid-like microglia, but not the ramified-like microglia, expressed the MHC class 1
protein (arrow and arrowhead, respectively) (Iba1 (g, h red), MHC class I (g, i green), DAPI (g–j blue)). Electron microscopy revealed that differentiated
cells have microglial traits and show increased electron density at the cytoplasmic periphery (k, arrow). Iba1+ ameboid-like microglia were able to
phagocytose latex beads (Iba1 (l red), latex beads (l green), DAPI (l blue)). Scale bars= 50 μm (b, c), 20 μm (d, g), 1 μm (k), and 10 μm (l) Iba1 ionized
calcium binding adaptor molecule 1, MACS magnetic cell sorting, MHC major histocompatibility complex, PDGFRβ platelet-derived growth factor receptor-β
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Brain PCs have the potential to generate microglia
following ischemia
To confirm that reactive brain PCs can develop into
microglia following ischemia, MACS-sorted, clustered
PDGFRβ+ iPCs (Fig. 5a) were induced to differentiate.
To exclude potential contamination with perivascular
macrophages, the spheres were immunostained with
CD68. The cell clusters expressed Iba1 (Fig. 5b) but not
CD68 (Fig. 5c), indicating that they did not contain peri-
vascular macrophages. In addition, the differentiated
cells expressed Iba1 and some also expressed CD11b, an
integrin receptor that serves as a microglial marker
(Fig. 5d–f ). Morphologically, the differentiated Iba1+
cells displayed the traits of both ramified and ameboid
microglia (Fig. 5g, h, j). Iba1+ ameboid-like microglia,
but not ramified-like microglia, expressed MHC class 1
(Fig. 5g, i, j). Electron microscopy revealed that these
cells also showed other microglial traits, including an in-
crease in the electron density observed at the cytoplas-
mic periphery (Fig. 5k). Since some Iba1+ cells displayed
an ameboid-like microglial phenotype (Fig. 5g–j), we fur-
ther investigated whether the differentiated cells pos-
sessed a phagocytic capacity by exposing them to latex
beads. We found that Iba1+ ameboid-like microglia took
up the latex beads (Fig. 5l), indicating that reactive brain
PCs can produce functional, phagocytic microglia.
Brain PCs acquire stem cell and microglial traits following
ischemia/hypoxia
Thus far, our data showed that brain PCs acquire specific
stemness and microglial phenotypes in response to ische-
mia/hypoxia. However, the mechanism by which they
Fig. 6 Oxygen/glucose deprivation induces brain PCs to acquire the traits of stem cells and microglia. Normal brain pericytes (PC-N) (a) were
subjected to OGD (b). Immunohistochemistry showed that PC-N were positive for various pericytic markers, including PDGFRβ (PDGFRβ (c green),
DAPI (c blue)), NG2 (NG2 (d green), DAPI (d blue)), and αSMA (αSMA (e green), DAPI (e blue)). PC-N expression of these pericytic markers was
confirmed by RT-PCR (f). Following OGD treatment, PC-OGD showed a gradual decrease in pericytic/mesenchymal marker gene expression,
including for NG2, PDGFRβ, and αSMA. In contrast, expression of the stem/epithelial cell marker Sox2 was upregulated (g). PC-OGD that
formed cell clusters (h, i) showed strong expression of the stem cell markers Sox2 and nestin compared with that in the control cells (j). In addition,
PC-OGD-associated cell clusters expressed Iba1 and CD11b (k). Scale bars= 50 μm (a, c, d, e, i) PC-N PCs cultured under normal/normoxia condition,
PC-OGD PCs cultured under oxygen/glucose deprivation
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acquired these traits remains unclear. To investigate this
mechanism, commercially available, normal brain PCs
(PC-N) (Fig. 6a) were incubated under OGD conditions
(Fig. 6b) to mimic ischemia/hypoxia. Immunohistochem-
istry showed that PC-N express various pericytic markers,
including PDGFRβ (Fig. 6c), NG2 (Fig. 6d), and αSMA
(Fig. 6e). The RT-PCR results confirmed the PC-N expres-
sion of these markers (Fig. 6f). After OGD treatment (PC-
OGD), pericytic/mesenchymal marker (PDGFRβ, NG2,
and αSMA) expression was downregulated, while that of a
stem/epithelial marker Sox2 was upregulated (Fig. 6g).
These observations indicate that brain PCs develop stem-
ness in a mesenchymal-epithelial transition (MET)-like
manner.
However, PC-OGD did not express nestin and Iba1
(Fig. 6g). Thus, we further investigated whether PC-
OGD acquire microglial phenotypes in parallel with an
increase stem cell traits. In this study, PC-OGD were
further incubated in floating cultures to develop stem-
ness (Fig. 6h) as described previously [20]. Under these
conditions, PC-OGD formed cell clusters (Fig. 6i) and
they significantly increased their expression of stem cell
markers, such as Sox2 and nestin (Fig. 6j). In contrast,
control PC-N that formed cell clusters only weakly
expressed these markers (Fig. 6j). Furthermore, we found
that the PC-OGD that formed cell clusters expressed
significantly elevated amounts of the microglial markers
Iba1 and CD11b (Fig. 6k). These results suggest that
brain PCs develop stemness following ischemia/hypoxia,
thereby acquiring microglial phenotypes.
Discussion
The multipotent stem cell activity of PCs, which allows
them to differentiate into various cell types, including
adipocytes, osteoblasts, chondrocytes, neural cells, and
vascular cells, has been well documented [16, 25, 26,
37–43]. Previous reports have shown that PCs can dif-
ferentiate into immune cells such as dendritic cells [44]
and macrophage-like cells [45]. However, the ability of
PCs to produce microglia has remained unclear because
most reported studies based their investigation on ultra-
structural findings alone [17–19, 23]. Although a recent
report showed that brain PCs acquire a microglial
phenotype after ischemia [36], the precise mechanism
was not elucidated. The current study clearly demon-
strated that brain PCs acquire multipotent VSC activity
following ischemic stroke and can therefore produce
functional microglia.
VSCs are capable of differentiating into multiple cell
lineages [9, 14, 46]. Although the precise traits of these
cells remain unclear, PCs located around capillaries are
strong candidate VSCs, as are APCs located around lar-
ger vessels [9]. APCs are Sca1+, multipotent stem/pro-
genitor cells that localize in the adventitia of blood
vessels [47]. Similar to the traits of multipotent PCs [20],
APCs exhibit the potential for multi-lineage differenti-
ation into various cell populations, including adipocytes,
osteoblasts, chondrocytes, myocytes, neural cells, and
vascular cells [10–12, 48]. In addition, a recent study by
Psaltis and colleagues showed that APCs, but not bone
marrow cells, give rise to macrophages that co-express
αSMA [13, 49]. Combined with the present results
showing that αSMA was predominantly present at peri-
vascular cells around large vessels, these findings suggest
that APCs rather than PCs have the potential to produce
macrophages. Furthermore, our current study showed
that Iba1+ microglia expressed PDGFRβ but not αSMA,
suggesting that PCs rather than APCs have the potential
to produce microglia. The precise relationship between
APCs and PCs remains unclear. However, since APCs
and PCs both express several markers and display simi-
lar traits [14], both are likely to be multipotent VSCs
that can produce cells of the microglia/macrophage
lineage.
Consistent with our previous studies [20, 50], the
current study demonstrated that PCs derived from the
post-ischemic brain expressed various stem/undifferenti-
ated cell markers as well as multipotency. Why do react-
ive PCs acquire multipotency following an ischemic
stroke? Under normal conditions, PCs are quiescent
cells that cycle slowly. However, upon stimulation, PCs
proliferate, migrate, and differentiate into various cell
types [25, 26, 51]. These characteristics suggest that PCs
alter their phenotypes under pathologic conditions. In
support of this concept, our previous and current studies
demonstrated that brain PCs cultured under conditions
of OGD and in a MET-like manner can be repro-
grammed to become multipotent stem cells that express
various stem/undifferentiated cell markers, including
nestin, c-myc, Klf4, and Sox2 [20, 50]. These findings in-
dicate that the properties of PCs under normal and
pathological conditions are completely distinct and that
reactive, but not quiescent, PCs are likely multipotent
VSCs that can produce cells of various lineages.
In the present study, we found that PC-OGD that
formed cell clusters further increased their expression of
stem cell markers, such as Sox2 and nestin. In addition,
PDGFRβ+ iPCs showed that pericytic markers were pre-
dominantly expressed in the peripheral zones of cell
clusters but not in the cores. Although we do not know
the exact reason for this phenomenon, the current study
showed that pericytic marker expression was downregu-
lated during MET that occurred following ischemia/hyp-
oxia [20]. Therefore, MET most likely occurs within the
hypoxic cores of cell clusters rather than in the periph-
eral zones.
Previous studies have shown that within brains under
pathologic conditions, the pericytic marker NG2 was
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expressed in microglia determined to have multipotency
[22, 52]. Consistent with these reports, we found that
some NG2+ cells within ischemic areas expressed the
microglial marker Iba1 (data not shown). Although it re-
mains unclear whether NG2+ PCs can transform into
microglia under these conditions, the present study
showed that reactive PCs expressing PDGFRβ acquire
stemness and can produce microglia. These results indi-
cate that it is possible that some NG2+ microglia origin-
ate from PCs following injury. Together, these finding
suggest that reactive PCs acquire not only stemness but
also hematopoietic potential since microglia/macro-
phage-like cells have been reported to be derived from
hematopoietic lineage cells, including hematopoietic
stem cells [53, 54]. Why do reactive PCs acquire
hematopoietic potential? Although adult brain PCs lack
angiogenic properties under normal conditions, multipo-
tent PCs do exhibit vasculogenic traits [40, 43, 55]. In
addition, APCs expressed both PC (PDGFRβ, NG2) and
hematopoietic stem cell (CD34) markers [40, 43, 55].
Furthermore, we recently demonstrated that following
ischemia/hypoxia, adult brain PCs display a complex
angioblastic phenotype that includes the expression of
various hematopoietic stem cell markers such as CD34
and CD144 in addition to their original mesenchymal
properties [20]. These cells acquired angioblastic traits
along with enhanced expression of pluripotent markers
such as Klf4 [20], which promotes angioblastic lineage
reprogramming [56]. Combined with the finding that
PDGFRβ is expressed in early hematopoietic precursors
during development [57], these findings suggest that is-
chemia/hypoxia may convert normal PCs into reactive
PCs with a mesenchymoangioblastic phenotype, which is
typically observed in immature PCs during development
[57, 58]. Nevertheless, the precise traits and subtypes of
multipotent PCs with hematopoietic potential should be
determined, ideally through future studies that include
pericyte genetic lineage labeling experiments.
Conclusions
We have demonstrated that reactive PCs give rise to
microglia following ischemic stroke, suggesting that PCs
play an important role in mediating inflammation under
pathological conditions. Since reactive PCs can acquire
multipotent stem cell activity and thus can differentiate
into neural and vascular cells [20], our results indicate
that brain PCs, a key component of the neurovascular
unit that comprises neural cells, vascular cells, and
microglia [59], can produce all components of this func-
tional unit in response to ischemia/hypoxia. As the neu-
rovascular unit serves as the minimal functional unit in
the CNS, reactive PCs could potentially be targeted to
regulate regeneration following CNS injury.
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post-stroke day 5 (M–P) (PDGFRβ (N, O: red), CD68 (N, P: green), DAPI
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